Skip to main content

Advertisement

Table 3 Baseline characteristics among the 66 patients who received palliative systemic treatment

From: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Characteristic Frequency %
  Median (years) 54 (range, 22-78)
Age <60 42 63.6
  ≥ 60 24 36.4
Sex Male 41 62.1
  Female 25 37.9
  Absent 61 92.4
Carcinoid symptom Present 3 4.5
  Unavailable 2 3.0
  Pancreas 2 3.0
  GI 15 22.7
Origin Lung 15 22.7
  Etc.* 22 33.3
  Unknown 12 18.2
  Local 10 15.2
Prior stage Regional 9 13.6
  Distant 47 71.2
Grade 1 20 30.3
  2 1 1.5
  3 10 15.2
  Large 8 12.1
  Small 5 7.6
  Unclassified 15 22.7
  Unavailable 7 10.6
  24-hour urine 5-HIAA (μmol/day) Median (range) 33.5 (6.8-341.2)
   <31.4 5 45.5%
Biomarkers   ≥ 31.4 6 54.5%
   Median (range) 1.36 (0.2-23.1)
  Serum NSE (nmol/l) <1.0 8 36.4%
   ≥ 1.0 14 63.6%
  1. Abbreviations as in table 1, 2
  2. *The uterus (4 cases), biliary tract (3), thymus (3), mediastinum (2), oral cavity (2), skin (2), trachea (1), kidney (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)
  3. Available data: 11
  4. Available data: 22